Literature DB >> 22296399

Low frequency of human T-cell lymphotropic virus 1 antibodies in Iranian gastric cancer patients in comparison to controls.

Seyed Mohammad Ebrahim Tahaei1, Seyed Reza Mohebbi, Seyed Reza Fatemi, Parvaneh Mohammadi, Fatemeh Nemati Malek, Pedram Azimzadeh, Shohreh Almasi, Dariush Mirsattari, Mohammad Reza Zali.   

Abstract

There is some evidence that human T-cell lymphotropic virus (HTLV-1) infection has a reverse association with gastric cancer (GC). Data about this association in the Iranian population are scarce. In this study we therefore assessed the frequency of anti-HTLV-1 antibody in GC patients and compare it to antibody presence in healthy individuals in Iranian population. This case control study was performed between 2008-2011 on 201 GC patients and 219 control subjects. HTLV-1 antibodies were assessed by ELISA and the positive results were confirmed by western blotting. Totals of 201 gastric cancer patients and 219 controls were enrolled in this study. The tumors in the majority of patients (45.3%) were in the distal (non-cardia) area. Mean age of patients at the time of diagnosis was 59.2±12.5 and mean age of controls was 57.7±11.3. While only one GC patient (0.5%) was positive for HTLV-1 antibody, there were four individuals (1.89%) from the control group with antibodies. In addition, smoking had statistically significant relationship with cancer (P=0.001). Our study showed that the frequency of HTLV-1 antibody in patients was lower than in controls, similar to the results obtained in Japan. Further investigations with a larger sample size are needed in order to determine the association between GC and HTLV-1 infection in Iran.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22296399

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  7 in total

1.  Relationship Among Strongyloides stercoralis Infection, Human T-Cell Lymphotropic Virus Type 1 Infection, and Cancer: A 24-Year Cohort Inpatient Study in Okinawa, Japan.

Authors:  Teruhisa Tanaka; Tetsuo Hirata; Gretchen Parrott; Miwa Higashiarakawa; Takeshi Kinjo; Tetsu Kinjo; Akira Hokama; Jiro Fujita
Journal:  Am J Trop Med Hyg       Date:  2015-11-30       Impact factor: 2.345

Review 2.  The Double-Edged Sword Role of Viruses in Gastric Cancer.

Authors:  Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska; Rafał Hrynkiewicz; Mikołaj Wołącewicz; Rafał Becht; Jacek Roliński
Journal:  Cancers (Basel)       Date:  2020-06-24       Impact factor: 6.639

3.  Clinical Features of Breast Cancer Patients with Human T-Cell Lymphotropic Virus Type-1 Infection.

Authors:  Munetsugu Hirata; Yoshiaki Shinden; Ayako Nagata; Yuki Nomoto; Hazuki Saho; Akihiro Nakajo; Takaaki Arigami; Hiroshi Kurahara; Kosei Maemura; Shoji Natsugoe; Yuko Kijima
Journal:  Asian Pac J Cancer Prev       Date:  2019-06-01

Review 4.  Small cells lung epidermoid carcinoma in a HTLV1-infected patient: case report and literature review.

Authors:  Flávia Esper Dahy; Renata Basic Palhares; Tatiane Assone; Jerusa Smid; João Victor Luisi de Moura; Michel E J Haziot; Rosa Maria N Marcusso; Augusto César Penalva de Oliveira; Jorge Casseb
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2021-04-26       Impact factor: 1.846

5.  Evaluation of antibody frequency against HBV, HCV and HTLV-1.

Authors:  Seyed Mohammad Ebrahim Tahaei; Seyed Reza Mohebbi; Seyed Reza Fatemi; Pedram Azimzadeh; Dariush Mirsattari; Azar Sanati; Afsaneh Sharifian
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2012

Review 6.  Epidemiologic Study of Gastric Cancer in Iran: A Systematic Review.

Authors:  Khadijeh Kalan Farmanfarma; Neda Mahdavifar; Soheil Hassanipour; Hamid Salehiniya
Journal:  Clin Exp Gastroenterol       Date:  2020-11-05

7.  Associations Between Gastric Cancer Risk and Virus Infection Other Than Epstein-Barr Virus: A Systematic Review and Meta-analysis Based on Epidemiological Studies.

Authors:  Hui Wang; Xiao-Long Chen; Kai Liu; Dan Bai; Wei-Han Zhang; Xin-Zu Chen; Jian-Kun Hu
Journal:  Clin Transl Gastroenterol       Date:  2020-07       Impact factor: 4.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.